Quantitative analysis of biochemical processes in living cells at a single-molecule level: a case of olaparib–PARP1 (DNA repair protein) interactions. Issue 23 (2nd November 2021)

• Record Type: Journal Article
• Authors: Karpińska, Aneta; Pilz, Marta; Buczkowska, Joanna; Żuk, Paweł J.; Kucharska, Karolina; Magiera, Gaweł; Kwapiszewska, Karina; Hołyst, Robert
• Is Part Of: Analyst. Volume 146:Issue 23(2021)
• Page Start: 7131
• Page End: 7143
• Publication Date: 2021-11-02
• Subjects: Chemistry, Analytic -- Periodicals; 543
• DOI: 10.1039/d1an01769a
• Languages: English
• ISSNs: 0003-2654

Abstract

Abstract : Fluorescence correlation spectroscopy was applied to quantify drug-target interactions directly in living human cells. Abstract : Quantitative description of biochemical processes inside living cells and at single-molecule levels remains a challenge at the forefront of modern instrumentation and spectroscopy. This paper demonstrates such single-cell, single-molecule analyses performed to study the mechanism of action of olaparib – an up-to-date, FDA-approved drug for germline-BRCA mutated metastatic breast cancer. We characterized complexes formed with PARPi-FL – fluorescent analog of olaparib in vitro and in cancer cells using the advanced fluorescent-based method: Fluorescence Correlation Spectroscopy (FCS) combined with a length-scale dependent cytoplasmic/nucleoplasmic viscosity model. We determined in vitro olaparib–PARP1 equilibrium constant (6.06 × 10 8 mol L −1 ). In the cell nucleus, we distinguished three states of olaparib: freely diffusing drug (24%), olaparib–PARP1 complex (50%), and olaparib–PARP1–RNA complex (26%). We show olaparib accumulation in 3D spheroids, where intracellular concentration is twofold higher than in 2D cells. Moreover, olaparib concentration was tenfold higher (506 nmol L −1 vs. 57 nmol L −1 ) in cervical cancer (BRCA1 high abundance) than in breast cancer cells (BRCA1 low abundance) but with a lower toxic effect. Thus we confirmed that the amount of BRCA1 protein in the cells is a better predictor of the therapeutic effect of olaparib than its penetration into cancer tissue. Our single-molecule and single-cell approach give a new perspective of drug action in living cells. FCS provides a detailed in vivo insight, valuable in drug development and targeting.